Eli Lilly and Company: all 2,262 studies
Page 16 of 23. Open to participants first (177), then studies with results posted, then the rest; newest registration first within each.
- A Study of LY4268989 (MORF 057) in Healthy ParticipantsCompletedNCT07707375Phase 1
- A Study of Eloralintide (LY3841136) in Healthy ParticipantsCompletedNCT07701083Phase 1
- A Study of Food Effect on Tersolisib (LY4064809) in Healthy ParticipantsCompletedNCT07662798Phase 1
- A Study of LY4065967 in Healthy ParticipantsCompletedNCT07607483Phase 1
- A Study of the Effects of Itraconazole on LY4395089 in Healthy ParticipantsCompletedNCT07592572Phase 1
- A Study of Eltrekibart (LY3041658) in Healthy ParticipantsCompletedNCT07545590Phase 1
- A Study of [14C]-LY4064809 in Healthy ParticipantsCompletedNCT07519525Phase 1
- A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or ObesityActive, not recruitingNCT07476118Phase 1
- A Study of Olomorasib (LY3537982) in Healthy ParticipantsCompletedNCT07439250Phase 1
- A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or ObesityActive, not recruitingNCT07438444Phase 4
- A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal FunctionCompletedNCT07426380Phase 1
- A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightActive, not recruitingNCT07357415Phase 3
- A Study of Remternetug (LY3372993) in Healthy Chinese ParticipantsCompletedNCT07346495Phase 1
- A Study of LY4064809 in Healthy Adult ParticipantsCompletedNCT07339735Phase 1
- A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes MellitusCompletedNCT07313813Phase 1
- A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes MellitusActive, not recruitingNCT07299084Phase 1
- A Study of LY4064809 in Healthy Adult Chinese ParticipantsCompletedNCT07247357Phase 1
- A Study of LY3549492 in Healthy Participants and Participants With Overweight or ObesityCompletedNCT07232732Phase 1
- A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightActive, not recruitingNCT07232719Phase 3
- A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise HealthyActive, not recruitingNCT07225556Phase 1
- A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesActive, not recruitingNCT07215559Phase 2
- A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal InsulinActive, not recruitingNCT07215312Phase 2
- A Study of How the Body Absorbs LY3537031CompletedNCT07202871Phase 1
- A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal ImpairmentCompletedNCT07165015Phase 1
- Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood CancersActive, not recruitingNCT07162181Phase 2
- A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeActive, not recruitingNCT07153471Phase 3
- A Study of LY4064912 in Healthy Participants and With Overweight or ObesityTerminatedNCT07152002Phase 1
- A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney FunctionCompletedNCT07137689Phase 1
- A Study of Olomorasib (LY3537982) in Healthy Japanese ParticipantsCompletedNCT07124013Phase 1
- A Study of LY3549492 in Chinese Participants With Type 2 Diabetes MellitusCompletedNCT07073170Phase 1
- A Study of Remternetug (LY3372993) in Healthy ParticipantsCompletedNCT07056309Phase 1
- A Study of LY4175408 in Participants With Advanced CancerActive, not recruitingNCT07046923Phase 1
- A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy ParticipantsCompletedNCT07044271Phase 1
- A Study of [14C]-LY4065967 in Healthy ParticipantsCompletedNCT07039045Phase 1
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainActive, not recruitingNCT07035093Phase 3
- A Study of LY3985863 in Healthy ParticipantsCompletedNCT07030127Phase 1
- A Study of LY3867070 in Healthy ParticipantsCompletedNCT07021547Phase 1
- A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch BurdenCompletedNCT07006792Phase 4
- A Study of LY3981314 in Healthy ParticipantsActive, not recruitingNCT07005284Phase 1
- A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesActive, not recruitingNCT06993792Phase 3
- A Study of Food Effect and Esomeprazole on LY4064809 in Healthy Adult ParticipantsCompletedNCT06991179Phase 1
- A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes MellitusActive, not recruitingNCT06982859Phase 1
- A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to HypoglycemiaCompletedNCT06982846Phase 1
- A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy ParticipantsCompletedNCT06977880Phase 1
- A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 DiabetesActive, not recruitingNCT06972472Phase 3
- A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityActive, not recruitingNCT06972459Phase 3
- A Study of LY4268989 (MORF-057) in Healthy ParticipantsCompletedNCT06964776Phase 1
- A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or OverweightActive, not recruitingNCT06962280Phase 3
- A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2Active, not recruitingNCT06952530Phase 3
- A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1Active, not recruitingNCT06948435Phase 3
- A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)Active, not recruitingNCT06948422Phase 3
- A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 DiabetesCompletedNCT06945419Phase 1
- A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DC-853 in Healthy ParticipantsCompletedNCT06937411Phase 1
- A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot DermatitisCompletedNCT06921759Phase 3
- Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach AcidTerminatedNCT06916143Phase 1
- A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or OverweightCompletedNCT06916091Phase 1
- A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver FunctionCompletedNCT06916078Phase 1
- A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or ObesityCompletedNCT06916065Phase 1
- A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or OverweightActive, not recruitingNCT06914895Phase 3
- A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 DiabetesWithdrawnNCT06901349Phase 2
- A Study of LY4064809 [14C]-STX-478 in Healthy Male ParticipantsCompletedNCT06901336Phase 1
- A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy ParticipantsCompletedNCT06890611Phase 1
- A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese ParticipantsCompletedNCT06869018Phase 1
- A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)Active, not recruitingNCT06864026Phase 4
- A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid ArthritisTerminatedNCT06859294Phase 2
- A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With ObesityActive, not recruitingNCT06859268Phase 3
- Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular DegenerationActive, not recruitingNCT06856577Phase 3
- A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or OverweightCompletedNCT06824051Phase 1
- A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use DisorderCompletedNCT06817356Phase 2
- A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque PsoriasisCompletedNCT06808815Phase 1
- To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy ParticipantsCompletedNCT06808802Phase 1
- A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy ParticipantsCompletedNCT06719128Phase 1
- A Study of LY4060874 in Healthy ParticipantsCompletedNCT06709820Phase 1
- Exploratory Safety and Efficacy of EMP-01 in Social Anxiety DisorderCompletedNCT06693609Phase 2
- A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy ParticipantsCompletedNCT06692348Phase 1
- A Study of LY4005130 in Healthy ParticipantsCompletedNCT06690996Phase 1
- A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or OverweightCompletedNCT06683508Phase 2
- A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityActive, not recruitingNCT06662383Phase 3
- A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)Active, not recruitingNCT06653153Phase 3
- A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightCompletedNCT06649045Phase 3
- A Study of [14C]-LY3866288 in Healthy ParticipantsCompletedNCT06644378Phase 1
- A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or OverweightCompletedNCT06643728Phase 2
- A Study of LY3866288 in Healthy ParticipantsCompletedNCT06641037Phase 1
- A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During RamadanCompletedNCT06635057Phase 4
- A Study of LY4100511 (DC-853) Mass Balance and Absolute Bioavailability of LY4100511 in Healthy Male ParticipantsCompletedNCT06627088Phase 1
- A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsActive, not recruitingNCT06607185Phase 1
- A Study of LY3537031 in Overweight, Obese, and Healthy ParticipantsActive, not recruitingNCT06606106Phase 1
- A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 DiabetesCompletedNCT06603571Phase 2
- A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative ColitisActive, not recruitingNCT06598943Phase 2
- Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney DiseaseWithdrawnNCT06598631Phase 2
- A Study of LY4065967 in Healthy Japanese ParticipantsCompletedNCT06594159Phase 1
- Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or OverweightCompletedNCT06588296Phase 3
- Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or OverweightCompletedNCT06588283Phase 3
- MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid TumorsActive, not recruitingNCT06586515Phase 1
- A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)CompletedNCT06584916Phase 3
- Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory PolyneuropathyCompletedNCT06568042Phase 2
- A Study of LY4050784 in Participants With Advanced or Metastatic Solid TumorsActive, not recruitingNCT06561685Phase 1
- A Study of LY3532226 in Participants With ObesityCompletedNCT06557356Phase 1
- Phase 2a Study of VTX3232 in Parkinson's DiseaseCompletedNCT06556173Phase 2
- A Study of Mevidalen (LY3154207) in Participants With Alzheimer's DiseaseCompletedNCT06538116Phase 2